Browse
Drugs
Pipeline drugs ranked by recent clinical activity, development stage, and industry relevance
Showing 10 of 100 featured drugs · 48,384 total tracked
| # | Drug | Sponsor | Phase | Indications | Trials |
|---|---|---|---|---|---|
| 1 | Keytruda GastroenterologyHematology+7 |  Merck & Co. | Phase 3 | 234 | 2159 |
| 2 | Cytoxan CardiovascularDermatology+12 |  Roche | Approved | 271 | 3001 |
| 3 | Decadron CardiovascularDermatology+13 |  Bristol-Myers Squibb | Approved | 384 | 2252 |
| 4 | Avastin CardiovascularDermatology+11 | Roche | Approved | 230 | 1998 |
| 5 | Taxol CardiovascularDermatology+7 |  Teva | Approved | 168 | 2209 |
| 6 | Opdivo CardiovascularGastroenterology+8 | Bristol-Myers Squibb | Phase 3 | 188 | 1479 |
| 7 | Rituxan CardiovascularDermatology+14 | Roche | Approved | 200 | 1815 |
| 8 | Gemzar Infectious DiseaseOncology+2 |  Johnson & Johnson | Approved | 121 | 1502 |
| 9 | Fludara DermatologyHematology+7 |  Sanofi | Approved | 117 | 1034 |
| 10 | Venclexta HematologyImmunology+6 |  AbbVie | Approved | 59 | 605 |